IMPROVING THE SYSTEM OF HEALTHCARE PROVISION FOR PATIENTS WITH DIFFUSE TOXIC GOITER IN UKRAINE
Author(s)
Vadziuk Y
Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine
Presentation Documents
OBJECTIVES: To assess medical technologies in order to increase efficiency and reduce the cost of thyroid disease treatment. METHODS: We made the retrospective analysis of 52 patients's medical records with diffuse toxic goiter that were hospitalized to the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The cost of thyrostatic therapy, which was preferred in practice, was analyzed. We also checked the appropriateness of diagnostics and specialist consultations according to the Protocol of medical care for patients with endocrine system disorders. RESULTS: The result of retrospective analysis of 52 patients's medical records with diffuse toxic goiter showed that all patients received thyrostatic therapy by thiamazol. Among them 13 patients were treated with drugs of Ukrainian production while 39 patients were taking medicine of foreign manufacturer. The cost of pharmacotherapy with foreign medicines was 275% more expensive compare to Ukrainian drugs. When comparing diagnostics and specialists consultations with a Protocol of medical care for patients with endocrine system disorders we have established compliance. However, given the prevalence of complications of underlying disease by cardiovascular system disorders (in 100% of patients), we consider it necessary to add cardiologist consultation to Protocol. CONCLUSIONS: It is advisable to use domestic drugs in pharmacotherapy of diffuse toxic goiter. Cardiologist consultation should be added to Protocol of medical care for patients with diffuse toxic goiter.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PDB91
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Diabetes/Endocrine/Metabolic Disorders